97 related articles for article (PubMed ID: 3103572)
1. [Tissue plasminogen activator (t-PA) in myocardial infarction. Biological aspects].
Samama M; Verdy E; Conard J; Vahanian A; Michel P; Van Dreden P; Nguyen G; Horellou MH; Combrisson A; Acar J
Arch Mal Coeur Vaiss; 1986 Oct; 79(11):1618-24. PubMed ID: 3103572
[TBL] [Abstract][Full Text] [Related]
2. [New thrombolytic agents in myocardial infarction].
Charbonnier B; Lang M; Brochier M
Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
[TBL] [Abstract][Full Text] [Related]
3. Non neutralizing antibodies to tissue type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein.
Cugno M; Cicardi M; Colucci M; Bisiani G; Merlini PA; Spinola A; Paonessa R; Agostoni A
Thromb Haemost; 1996 Aug; 76(2):234-8. PubMed ID: 8865537
[TBL] [Abstract][Full Text] [Related]
4. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery.
Paganelli F; Alessi MC; Morange P; Maixent JM; Lévy S; Vague IJ
Thromb Haemost; 1999 Jul; 82(1):104-8. PubMed ID: 10456462
[TBL] [Abstract][Full Text] [Related]
5. Clopidogrel-rt-PA-heparin combination in the treatment of acute myocardial infarction.
Bassand JP; Cariou R; Grollier G; Kragten J; Wolf JE; Heyndrickx GR
Semin Thromb Hemost; 1999; 25 Suppl 2():69-75. PubMed ID: 10440428
[TBL] [Abstract][Full Text] [Related]
6. [The absence of a procoagulant effect after TNK-t-PA: a comparison with streptokinase and rt-PA].
De Marco E; Andreotti F; van de Greef W; Quaranta G; Biasucci LM; Kol A; Maseri A; Rebuzzi AG
Cardiologia; 1998 Nov; 43(11):1209-13. PubMed ID: 9922587
[TBL] [Abstract][Full Text] [Related]
7. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].
Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R
Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348
[TBL] [Abstract][Full Text] [Related]
8. [Intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA) and urokinase in acute myocardial infarct: intermediate results of the G.A.U.S. study (German Activator Urokinase Study)].
Neuhaus KL; Tebbe U; Gottwik M; Weber MA; Feuerer W; Niederer W; Haerer W; Praetorius F; Grosser KD; Huhmann W
Klin Wochenschr; 1988; 66 Suppl 12():102-8. PubMed ID: 3126339
[TBL] [Abstract][Full Text] [Related]
9. Procoagulant properties of intravenous staphylokinase versus tissue-type plasminogen activator.
Okada K; Lijnen HR; Moreau H; Vanderschueren S; Collen D
Thromb Haemost; 1996 Dec; 76(6):857-9. PubMed ID: 8972000
[TBL] [Abstract][Full Text] [Related]
10. Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction.
van Griensven JM; Koster RW; Burggraaf J; Huisman LG; Kluft C; Kroon R; Schoemaker RC; Cohen AF
Clin Pharmacol Ther; 1998 Jan; 63(1):39-47. PubMed ID: 9465840
[TBL] [Abstract][Full Text] [Related]
11. [Platelet activation in the early phases of acute myocardial infarction].
Salvioni A; Giraldi F; Assanelli E; Lauri G; Grazi M; Pardea S; Marenzi G
Cardiologia; 1998 Aug; 43(8):825-32. PubMed ID: 9808873
[TBL] [Abstract][Full Text] [Related]
12. [Randomized double-blind study comparing tissue-type plasminogen activator with placebo in acute myocardial infarct].
Bleifeld W; Verstraete M; Brower RW; Collen D; Dunning AJ; Lubsen J; Michel PL; Schofer J; Vanhaecke J; Van de Werf F
Klin Wochenschr; 1988; 66 Suppl 12():86-92. PubMed ID: 3126349
[TBL] [Abstract][Full Text] [Related]
13. [t-PA in thrombolytic therapy of acute myocardial infarct].
Rutsch W; Schmutzler H
Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
[TBL] [Abstract][Full Text] [Related]
14. Streptokinase and rt-PA activate platelets by a different way: implications on the rethrombosis rate after their administration in myocardial infarction.
Parise P; Hauert J; Iorio A; Callegari P; Agnelli G
J Lab Clin Med; 1995 Feb; 125(2):212-21. PubMed ID: 7531212
[TBL] [Abstract][Full Text] [Related]
15. Thrombolysis in myocardial infarction (TIMI): update 1987.
Mueller HS
Klin Wochenschr; 1988; 66 Suppl 12():93-101. PubMed ID: 3126350
[TBL] [Abstract][Full Text] [Related]
16. [The safety and efficacy of systemic salvage thrombolysis in acute myocardial infarct].
Sarullo FM; Schicchi R; Schirò M; Americo L; Bonnì G; Faraone N; Di Pasquale P; Castello A; Mauri F
Ital Heart J Suppl; 2000 Jan; 1(1):81-7. PubMed ID: 10832123
[TBL] [Abstract][Full Text] [Related]
17. Fibrin-specific thrombolytic agents.
Collen D
Schweiz Med Wochenschr; 1987 Nov; 117(46):1791-8. PubMed ID: 3122317
[TBL] [Abstract][Full Text] [Related]
18. Sustained fibrinolysis after administration of t-PA despite its short half-life in the circulation.
Eisenberg PR; Sherman LA; Tiefenbrunn AJ; Ludbrook PA; Sobel BE; Jaffe AS
Thromb Haemost; 1987 Feb; 57(1):35-40. PubMed ID: 3109058
[TBL] [Abstract][Full Text] [Related]
19. Potential cost effectiveness of tissue plasminogen activator among patients previously treated with streptokinase.
Massel D
Can J Cardiol; 1999 Feb; 15(2):173-9. PubMed ID: 10079776
[TBL] [Abstract][Full Text] [Related]
20. [Hemorrhagic risk in intravenously administered thrombolytic treatment in acute myocardial infarction].
Acar J; Dorent R; Vahanian A; Michel PL; Cormier B; Slama M; Cazaux P; Conard J; Verdy E; Samama M
Arch Mal Coeur Vaiss; 1988 May; 81 Spec No():59-65. PubMed ID: 3142430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
